First Horizon Advisors’s Travere Therapeutics TVTX Stock Holding History

First Horizon Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-285	Closed	-$4.96K	–	2389
2024 Q4	$4.96K	Buy	+285	New	+$5.04K	﹤0.01%	1803
2023 Q3	–	Sell	-46	Closed	-$706	–	2506
2023 Q2	$706	Hold	46	–	–	﹤0.01%	2333
2023 Q1	$1.03K	Hold	46	–	–	﹤0.01%	2259
2022 Q4	$967	Hold	46	–	–	﹤0.01%	2253
2022 Q3	$1K	Hold	46	–	–	﹤0.01%	2195
2022 Q2	$1K	Buy	+46	New	+$1.16K	﹤0.01%	2279
2022 Q1	–	Sell	-46	Closed	-$1K	–	2273
2021 Q4	$1K	Hold	46	–	–	﹤0.01%	2173
2021 Q3	$1K	Buy	+46	New	+$845	﹤0.01%	2196

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

First Horizon Advisors's TVTX Position: Q1 2025 in Review

First Horizon Advisors sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 285 shares — an estimated $4.96K sold.

First Horizon Advisors first reported a position in TVTX in Q3 2021 and held it in 8 quarters. The position peaked at $4.96K in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

First Horizon Advisors reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
First Horizon Advisors sold 285 Travere Therapeutics shares in Q1 2025, an estimated $4.96K.
First Horizon Advisors first reported a position in Travere Therapeutics in Q3 2021 and held it in 8 quarters.
First Horizon Advisors's Travere Therapeutics position peaked at $4.96K in Q4 2024.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on First Horizon Advisors's 13F filing for Q1 2025, filed 28 Apr 2025.